Glucagon-like peptide-1 (GLP-1) receptor agonists, dual gastric inhibitory polypeptide (GIP)/GLP-1 receptor agonists, and pioglitazone have demonstrated efficacy in decreasing hepatic steatosis, resolving MASH, and reducing fibrosis in patients with type 2 diabetes and MASLD or MASH. The gene discussed is GIP; the disease is fatty liver disease.